Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276897 | 0.74 | — | — | |
| SCHEMBL1584536 | 0.74 | GAA (0.48) | GAAALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL21847337 | 0.73 | GAA (0.43) | GAAALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL812117 | 0.70 | GAA (0.44) | GAAALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL144976 | 0.70 | GAA (0.44) | GAAALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL12937360 | 0.70 | GAA (0.50) | GAAALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL16320893 | 0.70 | GAA (0.40) | GAAALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL3245939 | 0.69 | ALDH1A1 (0.40) | ALDH1A1TSHRTDP1 | |
| SCHEMBL66105 | 0.69 | — | — | |
| SCHEMBL7481733 | 0.69 | GAA (0.42) | GAAALDH1A1TSHRLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022065215-A1 | COMPOSITION, FILM, OPTICAL FILTER, SOLID-STATE IMAGING SENSOR, IMAGE DISPLAY DEVICE, INFRARED SENSOR, CAMERA MODULE, COMPOUND, AND INFRARED ABSORBER | 富士フイルム株式会社 | 2022-03-31 | — | — | WO | disclosed |
| WO-2021024863-A1 | ADHESIVE SHEET AND USE THEREOF | 日東電工株式会社 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021024741-A1 | LAYERED ARTICLE AND PEELING METHOD | 日東電工株式会社 | 2021-02-11 | — | — | WO | disclosed |
| WO-2020246529-A1 | ADHESIVE COMPOSITION AND SURFACE PROTECTIVE FILM | DIC株式会社 | 2020-12-10 | — | — | WO | disclosed |
| WO-2020218154-A1 | PRESSURE-SENSITIVE ADHESIVE SHEET AND USE THEREOF | 日東電工株式会社 | 2020-10-29 | — | — | WO | disclosed |
| EP-2342191-B1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-2342191-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-07 | — | — | US | disclosed |
| WO-2010030027-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-18 | — | — | WO | disclosed |
| EP-0705837-B1 | Preparation of 3-Oxy-5-oxo-6-heptenoic acid derivatives | UBE INDUSTRIES (JP) | 2002-08-07 | — | — | EP | disclosed |
| US-5744604-A | Preparation of 3-oxy-5-oxo-6-heptenoic acid derivatives | UBE INDUSTRIES, LTD. (JP) | 1998-04-28 | — | — | US | disclosed |
| US-5677455-A | Preparation of 3-oxy-5-oxo-6-heptenoic acid derivatives | UBE INDUSTRIES, LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| EP-0705837-A2 | Preparation of 3-Oxy-5-oxo-6-heptenoic acid derivatives | UBE INDUSTRIES, LTD. (JP) | 1996-04-10 | — | — | EP | disclosed |
| EP-0367235-B1 | Thienopyridine type mevalonolactones | NISSAN CHEMICAL IND LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-5026698-A | For reducing hyperlipidemia, hyperlipoproteinemia and atheroscierosis | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-25 | — | — | US | disclosed |
| EP-0367235-A1 | Thienopyridine type mevalonolactones | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | PDE10A, PDE3A, PDE3B | GAA 1833/4885ALDH1A1 1520/4885TSHR 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.